Radiopharm Theranostics (ASX:RAD) receives FDA designations for DUNP19
20 Sep 2022 - Radiopharm Theranostics Limited (ASX:RAD) CEO and Managing Director Riccardo Canevari discusses the FDA's award of orphan status and rare paediatric disease designation for the company's DUNP19 technology.